Oct. 29 at 2:12 PM
$AVTR Q3: Revenue & EPS Misses, Huge Impairment⚡
The BEAR Case (Why It's Down):
📉 Revenue Shortfall:
$1.62B, down 5.3% YoY and missing
$1.65B consensus by ~1.8%, organic decline of -4.7% undercut guided -4% to -2% range.
🔮 EPS Miss & No Guidance: Adjusted EPS
$0.22 fell short of
$0.23 estimates; no full-year outlook refresh adds uncertainty amid prior -2% to 0% organic growth forecast.
💸 Massive Writedown:
$785M non-cash goodwill impairment in Lab Solutions reflects "poorer actual and projected performance," highlighting structural pressures.
🛑 Segment Weakness: Lab Solutions -4.9% organic, Bioscience Production -4.3%, bioprocessing headwinds persist beyond "temporary" framing.
Bottom Line: Misses and the hefty impairment expose transition pains and market softness, eroding near-term trust despite buyback and CEO optimism
